TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7383476
Drug: 100‐mg clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100‐mg clotrimazole vaginal tablets, used once daily at bedtime for 7 days
Study: 25085960
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary revascularization with drug-eluting stents (DES-PCI)
Study: 22520932
Drug: Valsartan/Hydrochlorothiazide (V/HCTZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Hydrochlorothiazide (V/HCTZ) 160/12.5 mg
Study: 22520932
Drug: Valsartan (V)
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan (V) 160 mg
Study: 10424505
Drug: HFA cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA cromolyn sodium (2 mg, two inhalations, qid for 12 weeks)
Study: 10424505
Drug: CFC cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFC cromolyn sodium (2 mg, two inhalations, qid for 12 weeks)
Study: 21478216
Drug: Mannitol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (400 mg b.i.d.)
Study: 19583518
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for ASB
Study: 19583518
Drug: Treatment only
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment only for symptomatic infections
Study: 17889086
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of iron daily in the second half of pregnancy
Study: 15173273
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zoledronic acid (via a 15-minute infusion every 3 weeks for 15 months)
Study: 11346861
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zoledronic acid
Study: 11294919
Drug: Gabapentin 3,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 3,600 mg daily for 9 months
Study: 3410944
Drug: Sterile skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile skin preparation technique
Study: 29738561
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) amoxicillin/clavulanate 1750 mg IR twice a day (Period 2)
Study: 29738561
Drug: Standard-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (SD) amoxicillin/clavulanate 875/125 mg IR
Study: 29738561
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) amoxicillin/clavulanate 2000 mg ER (Period 1)
Study: 29738561
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) amoxicillin/clavulanate
Study: 29738561
Drug: Standard-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (SD) amoxicillin/clavulanate
Study: 26251590
Drug: Endobronchial valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial valve (EBV) therapy
Study: 23979267
Drug: component therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: component therapy (COMP)
Study: 21092076
Drug: docetaxel single-agent
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel single-agent (D)
Study: 19138237
Drug: Inhaled steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroid withdrawal for 12 weeks
Study: 19138237
Drug: Inhaled steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroid treatment (before withdrawal)
Study: 12113325
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL 25% sucrose given orally 2 min before heel prick
Study: 12113325
Drug: Milk intake
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk intake by nasogastric tube and 1 mL 25% sucrose given orally 2 min before heel prick
Study: 15148453
Drug: Polymyxin B-immobilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin B-immobilized fiber (PMX-F) treatment
Study: 1749827
Drug: Oral scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral scopolamine (1.2 mg)
Study: 6762044
Drug: 3% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% acyclovir (ACV) eye ointment
Study: 22383085
Drug: Esmolol (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (bolus of 0.5 mg·kg(‐1) iv at induction followed by infusion of 5‐15 μg·kg(‐1)·min(‐1))
Study: 22383085
Drug: Remifentanil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil plus ketamine (bolus of ketamine 0.5 mg·kg(‐1) iv and remifentanil 0.5 μg·kg(‐1) iv at induction followed by a remifentanil infusion titrated over a range of 0.1‐0.5 μg·kg(‐1)·min(‐1))
Study: 19403955
Drug: CCP (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCP (6 g/d CLA + 9 g/d C + 36 g/d P)
Study: 16426124
Drug: Diclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (100 mg/daily) plus aescin (80 mg/daily)
Study: 16426124
Drug: Diclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (100 mg/daily) plus aescin (80 mg/daily) plus tamsulosin (0.4 mg/daily)
Study: 8787684
Drug: Oltipraz 500
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 500 mg/m2
Study: 8787684
Drug: Oltipraz 1000
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 1000 mg/m2
Study: 1485740
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy and pharmacologic therapy for 12 patients
Study: 1485740
Drug: Pharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic therapy alone for 21 patients
Study: 15144165
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine (EBM) principles and methods
Study: 16195625
Drug: Valsartan added
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan added to conventional treatment (V group)
Study: 16195625
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (C group)
Study: 7556834
Drug: 0.3% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% chlorhexidine gel
Study: 7556834
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel vs combined placebo plus control group
Study: 2288318
Drug: Pitressin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitressin (6 or 10 units) administered by subcutaneous injection 30 minutes prior to contrast medium injection
Study: 2288318
Drug: Routine procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Routine procedure (laxatives the previous night and NPO the morning of the examination)
Study: 31006142
Drug: Laser-assisted hair
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-assisted hair removal treatment by trained nurses
Study: 23371961
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment
Study: 28279480
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with lower trust in treatment
Study: 16248986
Drug: Aprepitant 80
Normalized name: aprepitant 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 80 mg
Study: 17525168
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg
Study: 21866658
Drug: Danshen Chuanxiongqin
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen Chuanxiongqin Injection (DCI) 10 mL intravenously dripped in 250 mL normal saline, once daily for 7 to 10 days before PCI
Study: 21866658
Drug: Danshen Chuanxiongqin
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen Chuanxiongqin Injection (DCI)
Study: 21866658
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment of Western medicine and PCI (Control group)
Study: 19512973
Drug: Acute ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute ketamine administration (low dose: 75 ng/mL; high dose: 150 ng/mL)
Study: 20153142
Drug: Non-drug-using controls
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug-using controls
Study: 16624928
Drug: Infliximab (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (a monoclonal antibody to TNF)
Study: 16624928
Drug: Etanercept (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (a soluble TNF receptor fusion protein)
Study: 8268901
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (antihypertensive treatment)
Study: 4037442
Drug: Glucose +
Normalized name: Fora Test N'GO Advance Blood Glucose + B-Ketone Monitoring System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose + 100 mg X kg‐1 X d‐1 of ketoleucine (Group B)
Study: 4037442
Drug: Glucose +
Normalized name: Fora Test N'GO Advance Blood Glucose + B-Ketone Monitoring System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose + 200 mg X kg‐1 X d‐1 of ketoleucine (Group C)
Study: 28444716
Drug: Soft-chew formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft-chew formulation (100 mg ibuprofen)
Study: 28444716
Drug: Hard tablet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard tablet (reference, 100 mg ibuprofen)
Study: 28444716
Drug: Soft-chew formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft-chew formulation (3 chews)
Study: 28444716
Drug: Soft-chew formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft-chew formulation (8 chews)
Study: 22802437
Drug: Hygiene promotion
Normalized name: PROMOTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hygiene promotion and water treatment intervention
Study: 16213034
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication in ADHD/C subjects
Study: 12559061
Drug: 10 weekly
Normalized name: donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weekly group sessions emphasizing food label information
Study: 9581027
Drug: meso‐2,3‐dimercaptosuccinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: meso‐2,3‐dimercaptosuccinic acid (DMSA) at a dose of 30 mg kg‐1
Study: 9581027
Drug: D,L‐2,3‐dimercaptopropane‐1‐sulfonic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: D,L‐2,3‐dimercaptopropane‐1‐sulfonic acid (DMPS) at a dose of 30 mg kg‐1
Study: 8068949
Drug: Chemotherapy arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy arm (T-ALL patients: 26, B-ALL patients: 57)
Study: 28848332
Drug: CGA unit
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGA unit treatment
Study: 25168034
Drug: Lozenge +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge + Coach Calls (n = 357)
Study: 25168034
Drug: Lozenge (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge (n = 356)
Study: 17145534
Drug: High-dose three-dimensional
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose three-dimensional conformal radiotherapy (3DCRT) at 66 Gy, 2 Gy/fraction
Study: 14505088
Drug: Penciclovir (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penciclovir (intravenous formulation)
Study: 14505088
Drug: Topical penciclovir
Normalized name: penciclovir Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical penciclovir
Study: 14505088
Drug: Oral famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral famciclovir
Study: 9371351
Drug: Moderate-dose trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose trimethoprim (10 mg/kg/day)
Study: 9371351
Drug: High-dose trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose trimethoprim (20 mg/kg/day)
Study: 30616699
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate aqueous nasal spray (Nasonex) 100 mcg/day for four weeks
Study: 16366763
Drug: Cocaine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (300 mg)
Study: 21426558
Drug: Chiropractic spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic spinal manipulative therapy (SMT) plus home exercise program (HEP)
Study: 14742346
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy website (MoodGYM)
Study: 9161740
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2 g propacetamol and 50 mg ketoprofen (group 4)
Study: 9161740
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g propacetamol (group 2)
Study: 9161740
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ketoprofen (group 3)
Study: 8203367
Drug: Routine blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine blood flow at 419 mL/min
Study: 8203367
Drug: Low blood
Normalized name: Glucagon Emergency Kit for Low Blood Sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low blood flow at 200 mL/min
Study: 8203367
Drug: Stop flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop flow technique at 419 mL/min
Study: 8203367
Drug: Low blood
Normalized name: Glucagon Emergency Kit for Low Blood Sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low blood flow technique at 419 mL/min
Study: 2955955
Drug: Oxygenated autologous
Normalized name: chondrocytes, autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygenated autologous blood perfusion at 60 ml/min
Study: 12368787
Drug: Subacromial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial injection
Study: 27417703
Drug: Four times
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times daily insulin (q.i.d) regimen
Study: 27417703
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily insulin (b.i.d) regimen
Study: 23396509
Drug: Ribavirin (1000-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (1000-1200 mg/d) for 4 weeks
Study: 23536652
Drug: Ribavirin monotherapy
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin monotherapy
Study: 22493916
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group (Methylcobalamin)
Study: 19838812
Drug: Low SPGI
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low SPGI (< 25 microg/l)
Study: 19838812
Drug: Normal SPGI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal SPGI (>= 25 microg/l)
Study: 9202916
Drug: Droperidol 1
Normalized name: droperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1 mg
Study: 8694168
Drug: Droperidol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.5 mg
Study: 1654183
Drug: Splint combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splint combined with injection
Study: 6671816
Drug: Yoga program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga program (10 weeks, regular attendance, daily practice for white elders)
Study: 28771671
Drug: Tailored vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored vitamin K dosing regimen (based on index INR and body surface area)
Study: 28771671
Drug: Fixed-dose vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose vitamin K regimen (1 or 2 mg)
Study: 28771671
Drug: Tailored vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored vitamin K dosing regimen
Study: 28771671
Drug: Fixed-dose vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose vitamin K regimen
Study: 26249766
Drug: Ibuprofen lysinate
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen lysinate (Algidrin® Pediátrico, FARDI S.A.)
Study: 26249766
Drug: Ibuprofen base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen base (Dalsy®, Abbott Laboratories S.A.)
Study: 19947259
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Ibuprofen sustained release capsule)
Study: 19947259
Drug: Waiting group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting group (no treatment)
Study: 17391568
Drug: cis-isomer-rich tomato
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis-isomer-rich tomato sauce (26.4 mg total lycopene/100 g sauce; 45 % cis-isomers)
Study: 17391568
Drug: all-trans-rich tomato
Normalized name: all-trans-retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: all-trans-rich tomato sauce (32.5 mg total lycopene/100 g sauce; 5 % cis-isomers)
Study: 10977106
Drug: Beta-carotene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (50 mg, alternate days)
Study: 19509109
Drug: Oral hypoglycemic
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemic agents (OHA)
Study: 8444822
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (50 mg daily of oral zinc sulphate for 6 weeks)
Study: 3538262
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in one stage of the trial
Study: 3538262
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment in adjacent stage
Study: 11016522
Drug: Modified assertive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified assertive community treatment
Study: 26948484
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment at community mental health centres
Study: 25491618
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose fentanyl (2 mcg/kg)
Study: 25491618
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fentanyl (40-70 mcg/kg)
Study: 18375321
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (SA)
Study: 16636210
Drug: Ximelagatran, 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran, 36 mg twice daily
Study: 15701910
Drug: Warfarin (adjusted-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (adjusted-dose aiming for INR 2.0 to 3.0)
Study: 18574928
Drug: Ximelagatran and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran and Warfarin
Study: 17329296
Drug: Conventional antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotics (CA)
Study: 10658044
Drug: Water +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water + Carbohydrate (3.39 +/- 0.23 liters of solution containing 204 +/- 14 g of carbohydrate)
Study: 10658044
Drug: Carbohydrate (204
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (204 +/- 14 g in 0.49 +/- 0.03 liter of solution)
Study: 1831248
Drug: Epidural infusions
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusions of sufentanil citrate
Study: 1831248
Drug: Epidural infusions
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusions of morphine in 0.5% bupivacaine (MS-MARC)
Study: 1831248
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from initial sufentanil citrate infusions to MS-MARC
Study: 29098341
Drug: Roflumilast 100
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast 100 μg
Study: 30776650
Drug: Roflumilast 250
Normalized name: ROFLUMILAST 250MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 250 μg
Study: 30776650
Drug: Roflumilast 1000
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast 1000 μg
Study: 22247360
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with conventional combination therapy for 24 months
Study: 19201183
Drug: Lutein-fortified fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein-fortified fermented milk (high content, 16 mg lutein)
Study: 19201183
Drug: Lutein-fortified fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein-fortified fermented milk (low content, 8 mg lutein)
Study: 16326293
Drug: Magnesium sulfate,
Normalized name: MAGNESIUM SULFATE,ANHYDROUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulfate, 2 g/70 kg, infused intravenously during and for 3 days postoperatively
Study: 16326293
Drug: Codeine, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine, 60 mg/70 kg, given orally 4 times a day for 3 days
Study: 16326293
Drug: Diclofenac sodium,
Normalized name: diclofenac sodium, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac sodium, 75 mg, given orally twice a day for 3 days
Study: 9617980
Drug: Venlafaxine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (37.5 mg twice a day)
Study: 9617980
Drug: Venlafaxine (37.5-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (37.5-75 mg twice a day)
Study: 9617980
Drug: Mianserin (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (10-20 mg three times a day)
Study: 1978500
Drug: Remoxipride (150-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (150-600 mg/day)
Study: 1978500
Drug: Haloperidol (5-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5-45 mg/day)
Study: 7017492
Drug: Broncaspin suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broncaspin suspension (3 tablespoonfuls a day)